Effect of combined use of atorvastatin and hormonal therapy on serum prostate-specific antigen, urinary function, and quality of life of early prostate cancer patients in intensive care unit

Li Xiao¹, Jiaoe Liao²*
¹Department of Critical Care Medicine Area 1, ²Endocrine Diabetes Department Zone 2, Chenzhou First People's Hospital, Chenzhou 423000, Hunan Province, China

*For correspondence: Email: Jiaoe dred513@outlook.com

Sent for review: 19 February 2022
Revised accepted: 12 June 2022

Abstract

Purpose: To determine the effects of combined use of atorvastatin and hormonal therapy on serum levels of prostate-specific antigen (PSA), urinary function parameters, and quality of life (QOL) of intensive care unit (ICU) patients with early prostate cancer (PCa).

Methods: The clinical data for 90 PCa patients treated in ICU of Chenzhou First People’s Hospital, Chenzhou, China from July 2019 to July 2020 were retrospectively analyzed. The patients were divided into a reference group given intensity-modulated radiotherapy (n = 45), and a study group treated with intensity-modulated radiotherapy + atorvastatin + hormonal therapy (n = 45) sequentially as they were admitted. After the treatments, serum PSA levels of the patients were measured using enzyme-linked immunosorbent assay (ELISA), while QOL was measured based on Expanded Prostate Cancer Index Composite (EPIC). Urinary parameters were determined by measuring various urodynamic indicators.

Results: Compared with the reference group, the study group had significantly lower post-treatment serum levels of PSA and blood lipids, higher levels of urinary function indicators (except for residual urine volume), and higher scores in IIEF-5 and EPIC (p < 0.001).

Conclusion: These results demonstrate that the combined use of atorvastatin and hormonal therapy is a reliable method for improving urinary function and QOL in early PCa patients. Moreover, the combined treatment has potentials for reducing serum levels of PSA and blood lipids in PCa patients. These findings may be useful in the establishment of improved therapy for early PCa.

Keywords: Atorvastatin, Hormonal therapy, Early prostate cancer, Serum PSA, Urinary function, Quality of life

INTRODUCTION

Prostate cancer (PCa) is the most frequent malignant tumor in elderly men worldwide, with mortality ranking 5th among male malignancies, and first among genito-urinary tumors [1]. The incidence of PCa in China has increased significantly in recent years due to increases in...
the population of the aged, and changes in dietary habits. Radical prostatectomy, the first choice of current treatment for PCa, controls the differentiation and proliferation of tumor cells and prolongs survival of the patients [2]. However, since most PCa patients are in old-age category, with impaired body function and intolerance to surgery, radical prostatectomy does not result in satisfactory curative effect [3]. Studies have shown that PCa is androgen dependent. Thus, hormonal therapy may be a better treatment option for the disease. It has been confirmed that levels of lipid metabolism are associated with viability of tumor cells. Indeed, PCa patients often show evidence of abnormal lipid metabolism [4]. Hyperlipidemia facilitates the development and progression of cancer cells. Therefore, it may be reasonably speculated that inhibiting the growth of tumor cells by controlling lipid metabolism in PCa patients may be beneficial for the clinical treatment of the disease.

Atorvastatin, a drug used to regulate blood lipids, reduces cholesterol biosynthesis and controls the level of lipid metabolism. The effectiveness of atorvastatin has been demonstrated in elderly patients with diabetic nephropathy [5]. However, the effect of combined use of hormonal therapy and atorvastatin on PCa has not been investigated. In this study, the effects of combined treatment with atorvastatin and hormonal therapy on serum PSA, urinary function and QOL in ICU patients with early PCa were investigated.

METHODS

General patient profiles

The clinical data for 90 PCa patients treated in ICU of Chenzhou First People’s Hospital from July 2019 to July 2020 were retrospectively analyzed. The patients were divided into reference group and study group, based on their order of admission, with 45 patients in each group. This study was approved by the ethics committee of Chenzhou First People’s Hospital (approval no. 20190547), and followed the guidelines of Declaration of Helsinki [6].

Inclusion criteria

Patients in the following categories were included in the study: subjects meeting the diagnosis criteria for PCa in Diagnosis and Treatment Specifications for Prostate Cancer [7], and were diagnosed after pathological biopsy of the prostate, with clinical manifestations such as micturition urgency, hematuria, and frequent micturition; patients with NM stages of T1 and T2, without symptoms of clinical metastasis and local lymphadenectomy; subjects who were treated in ICU, and those who did not receive hormonal and immuno-related therapies before the present study.

Exclusion criteria

Patients whose conditions were complicated with diseases resulting in failure of major organs such as heart, liver and kidney, or failure of other important organs; patients with immune dysfunction or acute or chronic infections; patients with cognition impairment or mental disease; patients who failed to complete the treatment regime, and those who were unwilling to participate in the study.

Treatments

After admission, patients in the two groups received ICU treatment, and corresponding intervention measures were established according to their actual condition and clinical cases. These treatments included nutritional support, fluid infusion and oxygen treatment. Moreover, the patients’ vital signs were monitored. If any changes in signs occurred, timely intervention was carried out and the changes were reported to the attending doctor. In addition, there was frequent communication with the family members of the patients to enable them understand the function of the ICU so as to enhance compliance [8].

Patients in the reference group received intensity-modulated radiotherapy during their ICU stay. Positioning was done under a simulated CT machine, generally from L2 to 10 cm from the lower sciatic rim. The clinical target volume (CTV) included sub-clinical lesions such as prostate and bilateral seminal vesicles. The pelvic lymph node drainage area was delineated to avoid any invasion. The planning target volume (PTV) was delineated based on the CTV: 0.5 cm external exposure was conducted upwards, downwards, and to the left and right. In view of the fact that the rectum is behind the prostate, only 0.3 cm was enlarged at the front and back. At the same time, the adjacent parts susceptible to radiation such as the bulb of penis, femoral head, rectum and bladder were delineated. Integrated block was used for conformal radiation and correction of non-homogeneous tissues. The medical linear accelerator (model: XHA600C; Shandong Shinva Medical Instrument Co. Ltd.) was used for treatment. The irradiation dose used for CTV was 2.23 Gy each time, 5 times per week, and the
total dose was 78 Gy. The irradiation dose for PTV was 2.17 Gy each time, 5 times per week, with a total dose of 76 Gy. Rectum and bladder V70 < 25 %, femoral head V50 < 5 %, and pubis V70 < 25 % were carried out.

In addition to the above treatments, patients in the study group received atorvastatin in combination with hormonal therapy. More than 5 months before intensity-modulated radiotherapy, goserelin (NMPA approval no. J20160052; AstraZeneca Pharmaceutical Co. Ltd; specification: 3.6 mg/bottle/box) was subcutaneously injected at a dose of 3.6 mg each time, once every four weeks. After radiotherapy, 50 mg of the anti-androgen drug bicalutamide (NMPA approval no. J20150050; AstraZeneca Pharmaceutical Co. Ltd.; specification: 50 mg × 20 tablets/box) was given once daily. When the serum PSA level was reduced to below 0.2 ng/mL and remained stable for 3 months, the drug was discontinued, and 10 mg of atorvastatin (NMPA approval no. H20051408; Pfizer Pharmaceutical Co. Ltd.; specification: 20 mg) was administered once daily for 30 consecutive days.

**Evaluation of indicators/parameters**

**Serum PSA and blood lipid indicators**

After treatment, fasting venous blood (5 mL) was collected. The blood samples were allowed to coagulate, after which they were centrifuged to obtain sera. Serum PSA concentration was measured with ELISA kits (Shanghai Jingkang Bioengineering Co. Ltd.) according to the protocol specified on the kit manual. The serum levels of triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) were measured with an Automatic Biochemical Analyzer [model: BK-400; Biobase Biodustry (Shandong) Co. Ltd., using assay kits purchased from Shanghai Fusheng Industrial Co. Ltd.]

**Urinary function**

One month after treatment, various urodynamic indicators i.e., peak urinary flow, residual urine volume, bladder compliance, and maximum urethral pressure, were determined.

**Erectile function and sexual desire**

Erectile function and sexual desire after treatment were evaluated by international index of erectile function-5 (IIEF-5) [9]. The scores on this scale ranged from 0 to 24 points. A score less than 21 points indicated erectile dysfunction (ED).

**Quality of life (QOL)**

One month after the treatments, QOL was evaluated in the patients using the Expanded Prostate Cancer Index Composite (EPCI) which covered scores for symptoms in the domains of intestinal function, hormonal function, urine passage and sexual function [10]. The total score for each domain was 100 points, with a higher score representing higher QOL.

**Statistical analysis**

In this study, the data were processed with the professional statistical software SPSS version 24.0, while GraphPad Prism 7 (GraphPad Software, San Diego, USA) was used for graphics. Enumeration data are expressed as numbers and percentages [n (%)], and were compared using chi square ($\chi^2$) test. Measurement data are presented as mean ± standard deviation (SD), and were compared between the two groups using Student’s t-test. Differences were considered statistically significant at $p < 0.05$.

**RESULTS**

**Patients’ profiles**

No notable differences were observed in patient profiles such as mean age, TNM stages, maximum urethral pressure, and degree of educational attainment between the two groups ($p > 0.05$), as outlined in Table 1.

**PSA levels**

After treatment, the mean serum PSA values of the study and reference groups were 15.47 ± 1.59 and 22.30 ± 2.97, respectively. Thus, post-treatment mean serum PSA level was lower in the study group than in the reference group ($p < 0.001$, Figure 1).

**Urine passage**

All urinary function indicators, except residual urine volume, were higher in the study group than in the reference group after treatment ($p < 0.001$, Table 2).

**IIEF-5 score**

After treatment, the IIEF-5 scores were significantly higher in the study group (21.34 ± 1.4) than in the reference group (16.47 ± 1.53, $p < 0.001$).
Table 1: Comparison of patient profiles

| Parameter                  | Study group       | Reference group  | $\chi^2$ | P-value |
|----------------------------|-------------------|------------------|---------|---------|
| Mean age (years)           | 65.49±3.26        | 65.52±3.19       | 0.044   | 0.965   |
| BMI (kg/m²)                | 21.26±0.46        | 21.31±0.52       | 0.483   | 0.630   |
| TNM stage                  |                   |                  | 0.185   | 0.667   |
| T1                         | 28 (62.22)        | 26 (57.78)       |         |         |
| T2                         | 17 (37.78)        | 19 (42.22)       |         |         |
| Gleason score (points)     | 6.48±1.28         | 6.51±1.25        | 0.112   | 0.911   |
| Prostate volume (cm³)      | 31.27±4.38        | 31.31±4.46       | 0.043   | 0.966   |
| Mean duration of disease   | 3.28±0.73         | 3.31±0.69        | 0.200   | 0.842   |
| (months)                   |                   |                  |         |         |
| Peak urine flow (mL/sec)   | 5.18±0.26         | 5.22±0.31        | 0.663   | 0.509   |
| 72 h frequency of urination| 51.23±2.36        | 51.28±2.42       | 0.099   | 0.921   |
| Maximum urethral pressure  | 22.37±1.36        | 22.42±1.29       | 0.179   | 0.858   |
| (cm H₂O)                   |                   |                  |         |         |
| Smoking history            |                   |                  | 0.189   | 0.664   |
| Yes/No                     | 29/16             | 27/18            |         |         |
| Drinking history           |                   |                  | 0.443   | 0.506   |
| Yes/No                     | 28/17             | 31/14            |         |         |
| Marital status             |                   |                  |         |         |
| Married                    | 39 (86.67)        | 38 (84.44)       | 0.090   | 0.764   |
| Unmarried                  | 2 (4.44)          | 4 (8.89)         | 0.714   | 0.398   |
| Divorced                   | 4 (8.89)          | 3 (6.67)         | 0.155   | 0.694   |
| Educational degree         |                   |                  |         |         |
| College                    | 4 (8.89)          | 5 (11.11)        | 0.124   | 0.725   |
| High school                | 39 (86.67)        | 37 (82.22)       | 0.338   | 0.561   |
| Primary school             | 2 (4.44)          | 3 (6.67)         | 0.212   | 0.645   |
| Place of residence         |                   |                  | 0.403   | 0.525   |
| Urban area                 | 26 (57.78)        | 23 (51.11)       |         |         |
| Rural area                 | 19 (42.22)        | 22 (48.89)       |         |         |

Table 2: Comparison of post-treatment urinary parameters (mean ± SD, n = 45)

| Group            | Peak urinary flow (mL/s) | Residual urine volume (mL) | Bladder compliance (cm H₂O) | Maximum urethral pressure (cm H₂O) |
|------------------|--------------------------|-----------------------------|------------------------------|-----------------------------------|
| Study            | 16.28±2.37               | 72.17±9.27                  | 27.39±2.36                   | 37.28±3.46                        |
| Reference        | 12.35±2.35               | 95.47±8.19                  | 23.17±2.25                   | 33.27±3.16                        |
| t                | 7.899                    | 12.636                      | 8.682                        | 5.741                             |
| $P$-value        | <0.001                   | <0.001                      | <0.001                       | <0.001                            |

Table 3: Comparison of blood lipid levels (mean ± SD, n = 45)

| Group            | TC                | LDL-C              | TG                |
|------------------|-------------------|--------------------|-------------------|
| Study            | 9.48±1.47         | 6.47±0.83          | 5.48±0.73         |
| Reference        | 16.35±1.36        | 11.26±0.76         | 10.43±0.85        |
| t                | 23.012            | 25.551             | 29.636            |
| $P$-value        | <0.001            | <0.001             | <0.001            |

Blood lipid levels

Post-treatment levels of TC, LDL-C and TG were lower in the study group than in the reference group ($p < 0.001$, Table 3).

EPCI scores

After treatment, EPCI scores were significantly higher in the study group than in the reference group ($p < 0.001$), as presented in Table 4.

Figure 1: Between-group comparison of serum PSA level after treatment. *$P < 0.001$, ($t = 13.600$), vs study group
Table 4: Between-group comparison of EPCI scores after treatment (points, mean ± SD, n = 45)

| Group    | Urine passage | Intestinal function | Sexual function | Hormonal function |
|----------|---------------|---------------------|-----------------|------------------|
| Study    | 74.53±4.29    | 82.16±3.82          | 72.54±4.62      | 81.23±4.71       |
| Reference| 69.26±4.37    | 74.27±3.27          | 62.28±4.18      | 75.25±4.28       |
| T        | 5.773         | 10.526              | 11.047          | 6.303            |
| P-value  | <0.001        | <0.001              | <0.001          | <0.001           |

DISCUSSION

Prostate cancer (PCa) is a frequent malignancy in men aged 50 years and above, and it is a main cause of cancer-related death in men [11]. Presently, the incidence of PCa and the associated mortality rates have increased in China. A study has shown that the incidence of PCa depends significantly on androgen levels, and it was suggested that PCa may be radically cured if patients at the early stage receive timely medical or surgical treatment. However, at the advanced stage of the disease, androgens cannot be blocked in a timely manner using surgery or drugs, leading to poor treatment effect [12]. Therefore, early PCa diagnosis and treatment are of great importance. Intensity-modulated radiotherapy, a common treatment for early-stage PCA with high conformality, further increases the target irradiation dose and reduces radiation damage to surrounding tissues, resulting in better clinical outcomes than conventional radiotherapy [13]. The proliferation of PCa cells is dependent upon androgens, implying that hormonal therapy occupies an important position in the treatment of prostate cancer [14].

The combined use of goserelin and bicalutamide is the classical regimen for hormonal therapy. It blocks the hypothalamic - pituitary - adrenal axis (HPA axis) and luteinizing hormone, and reduces serum testosterone levels, thereby suppressing the progression of PCa [15]. In another study, it was also demonstrated that the combined use of radiotherapy and hormonal therapy was more effective in reducing PCa recurrence and prolonging the overall survival of PCa patients, when compared with the use of radiotherapy alone [16]. Moreover, it has been shown that most PCa patients exhibit abnormal lipid metabolism, with hyperlipidemia contributing to the occurrence and progression of cancer cells, a finding which may be beneficial in the clinical treatment of PCa [17]. In the present study, the clinical data of ICU patients with early PCa were retrospectively analyzed. Patients in both groups received intensity-modulated radiotherapy, while those in the study group received additional combined treatment with atorvastatin and hormonal therapy. The results obtained revealed significantly lower mean PSA level in the study group. The changes in serum levels of PSA, a single chain glycoprotein, reflects therapeutic effect in PCa tissues [18]. Atorvastatin suppresses androgen biosynthesis and inhibits PCa tumor tissue proliferation, thereby reducing serum PSA level. Urinary dysfunction, a common complication in PCa patients, causes upper urinary tract lesions, impairs kidney function, and leads to life-threatening renal failure [19].

In this study, treatment of the PCa patients with combination of atorvastatin and hormonal therapy resulted in normal differentiation and apoptosis of the surviving tumor cells. The patients became free from hormone dependence, with improved condition and accelerated recovery of urinary function [20]. Post-treatment comparison of QOL between the two groups showed that the various EPCI scores were higher in the study group, indicating that PCa was controlled and the QOL was enhanced by the combined treatment with atorvastatin and hormonal therapy.

Limitations of the study

There was no diversity in the source of subjects investigated in this study, since the enrolled subjects were in the same hospital. In addition, the study period was short, and the toxic and side effects of the treatments on patients were not evaluated. Therefore, the conclusion arising from the present study requires validation through further research.

CONCLUSION

The use of atorvastatin and hormonal combination therapy for the treatment of ICU patients with early PCa reduced serum PSA levels, improves urinary function, and enhances QOL. Further studies in this direction will be beneficial for establishing a better therapy for PCa.

DECLARATIONS

Acknowledgements

None provided.
Funding
None provided.

Ethical approval
None provided.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest
No conflict of interest associated with this work.

Contribution of Authors
We declare that this work was done by the authors named in this article, and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Li Xiao and Jiaoe Liao conceived and designed the study, collected, analyzed and interpreted the experimental data, drafted the manuscript and revised the manuscript for important intellectual content. Both authors read and approved the final manuscript.

Open Access
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/record), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES
1. Kearns JT, Holt SK, Wright JL, Lin DW, Lange PH, Gore JL. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Cancer 2018; 124(13): 2733-2739.
2. Miller EA, Pinsky PF, Black A, Andriele GL, Pierre-Victor D. Secondary prostate cancer screening outcomes by race in the prostate, lung, colorectal, and ovarian (PLCO) screening trial. Prostate 2018; 78(11): 830-838.
3. Huang FM, Li XH, Liang Y. Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer. Zhonghua Nan Ke Xue 2018; 24(8): 690-694.
4. Vander Weele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, Yamaguchi R, Wheeler D, Lack J, Cam M, et al. Genomic heterogeneity within individual prostate cancer foci impacts predictive biomarkers of targeted therapy. Eur Urol Focus 2019; 5(3): 416-424.
5. Zelefsky MJ, Pintipatcharalert A, Kollmeier M, Goldman DA, McBride S, Gorovets D, Zhang Z, Varghese M, Happersett L, Tyagi N, et al. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer. Eur Urol Oncol 2020; 3(6): 748-755.
6. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191-2194.
7. Froncio J, Bey E, Hamard A, Mohammad H, Gonzalez S, Greffier J, Chevallier T, de Forges H, Beregi JP, Droopy S. Early results of unilateral prostatic artery embolization as a focal therapy in patients with prostate cancer under active surveillance: Cancer prostate embolisation, a pilot study. J Vasc Interv Radiol 2021; 32(2): 247-255.
8. Parson W, Zhang L, Wan Z, He Y, Huang H, Xiang H, Wu X, Zhang K, Liu Y, Goodin S, et al. Atorvastatin and caffeine in combination regulates apoptosis, migration, invasion and tumorspheres of prostate cancer cells. Pathol Oncol Res 2020; 26(1): 209-216.
9. Zhu YC, Jiang XZ, Bai QK, Deng SH, Zhang Y, Zhang ZP, Jiang Q. Evaluating the efficacy of atorvastatin on patients with carotid plaque by an innovative ultrasonography. J Stroke Cerebrovasc Dis 2019; 28(3): 830-837.
10. Zhao J, Cheng Q, Liu Y, Yang G, Wang X. Atorvastatin alleviates early hypertensive renal damage in spontaneously hypertensive rats. Biomed Pharmacother 2019; 109: 602-609.
11. Murtola TJ, Syväli H, Tolonen T, Helminen M, Räikonen J, Koskimäki J, Pakarainen T, Kajia A, Isotai T, Kujala P, et al. Atorvastatin versus placebo for prostate cancer before radical Prostatectomy-A randomized, double-blind, placebo-controlled clinical trial. Eur Urol 2019; 74(6): 697-701.
12. Cheng ZJ, Dai TM, Shen YY, He JL, Li J, Tu J. Atorvastatin pretreatment attenuates ischemic brain edema by suppressing Aquaporin 4. J Stroke Cerebrovasc Dis 2018; 27(11): 3247-3255.
13. Facina CH, Campos SGP, Gonçalves BF, Goes RM, Vilamaior PSL, Taboga SR. Long-term oral exposure to safe dose of bisphenol A in association with high-fat diet stimulates the prostate lesions in a rodent model for prostate cancer. Prostate 2018; 78(2): 152-163.
14. Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest 2019; 129(1): 192-208.
15. Aksnessæther BY, Myklebust TÅ, Solberg A, Klepp OH, Skovlund E, Hoff SR, Fosså SD, Widmark A, Lund JÅ. Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiation therapy: Long-term follow-up of the Scandinavian prostate cancer group-7 trial. Int J Radiat Oncol Biol Phys 2020; 106(4): 706-714.

16. Ito K, Kobayashi M, Komiyama M, Naito S, Nishimura K, Yonese J, Hashine K, Saito S, Arai G, Shinohara M, et al. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial. Cancer 2020; 126(17): 3961-3971.

17. Cao Q, Song Z, Ruan H, Wang C, Yang X, Bao L, Wang K, Cheng G, Xu T, Xiao W, et al. Targeting the KIF4A/AR axis to reverse endocrine therapy resistance in castration-resistant prostate cancer. Clin Cancer Res 2020; 26(6): 1516-1528.

18. Brureau L, Emeville E, Helissey C, Thome JP, Multigner L, Blanchet P. Endocrine disrupting-chemicals and biochemical recurrence of prostate cancer after prostatectomy: A cohort study in Guadeloupe (French West Indies). Int J Cancer 2020; 146(3): 657-663.

19. Luo HC, Fu ZC, Wang XP, Cai LJ, Wang FM, Yin Q, Lin G, Chen ZH, Liao SG. Treating the primary in low burden metastatic prostate cancer: Where do we stand? Medicine (Baltimore) 2020; 99(51): e23715.

20. Zhang W, Zhou H, Qin M, Zhang X, Zhang J, Chai S, Song J. Efficacy of brachytherapy combined with endocrine therapy and external beam radiotherapy in the treatment of intermediate and high-risk localized prostate cancer. J BUON 2020; 25(5): 2405-2411.